AstraZeneca Targets $80 Billion Revenue by 2030

AstraZeneca PLC reported a 40% surge in annual pre-tax profits to $12.4 billion for 2025, with total revenue rising 8% to $58.7 billion. The growth was driven by strong demand for oncology treatments, as well as portfolios in rare diseases, respiratory, immunology, and cardiovascular, renal, and metabolism sectors. For 2026, the company projects mid-to-high single-digit revenue growth and low double-digit growth in core earnings per share.

Chief Executive Pascal Soriot has set a target of $80 billion in annual sales by 2030. To achieve this, the company is investing $15 billion in China and has secured a $50 billion manufacturing deal in the United States. To mitigate geopolitical risks, AstraZeneca became the first non-US drugmaker to sign a pricing deal with the White House in October 2025, granting it a three-year tariff exemption.

The company is aggressively expanding its pipeline to counter future patent losses for its diabetes drug Farxiga. This includes an $18.5 billion partnership with China's CSPC Pharmaceutical Group to develop weight-loss and diabetes medications and the acquisition of Modella AI. AstraZeneca currently has over 100 ongoing Phase 3 studies, with more than 20 readouts expected in 2026.

Additionally, the company increased its annual dividend by approximately 3% to $3.30 per share and transitioned its U.S. listing from Nasdaq to the New York Stock Exchange on February 2, 2026.